Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Edward Morrow Atkinson III, Executive Vice President and Chief Technical Operations Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a prominent biotechnology company with a market capitalization of $122.8 billion and strong financial health according to InvestingPro, reported selling 2,650 shares of the company’s common stock. The shares were sold on February 27 for approximately $475.34 each, totaling around $1.26 million. This transaction was conducted under a pre-established trading plan. Following the sale, Atkinson retains ownership of 19,352 shares. The company maintains impressive fundamentals with an 86.11% gross margin and healthy liquidity, as evidenced by a current ratio of 2.69. InvestingPro analysis indicates the stock is trading near its Fair Value, with 12 additional exclusive insights available to subscribers.
In other recent news, Vertex, Inc. reported its fourth-quarter financial results, showing adjusted earnings per share of $0.15, slightly exceeding analyst estimates of $0.14. The company also reported revenue of $178.5 million for the quarter, surpassing the consensus estimate of $176.9 million and marking a 15.2% year-over-year increase. Despite these positive results, Vertex issued guidance for the first quarter of 2025 that fell short of expectations, forecasting revenue between $175 million and $178 million, below the analyst projection of $180.3 million. For the full year 2025, the company expects revenue to be in line with the consensus estimate of $764 million, ranging from $760 million to $768 million. The company highlighted that its cloud revenues grew 27% year-over-year in Q4, reaching $76.9 million, and its Annual Recurring Revenue increased by 17.7% to $603.1 million. Vertex also announced plans for additional research and development investments of $14 million to $16 million for AI initiatives and emerging technologies. These developments are intended to drive long-term growth, according to Chief Financial Officer John Schwab. Despite a positive full-year outlook, the company’s shares declined significantly due to the weaker-than-expected Q1 guidance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.